FT
BBIO icon

Fiduciary Trust’s BridgeBio Pharma BBIO Stock Holding History

Fiduciary Trust’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$636K Buy
8,537
+578
+7% +$40.5K 0.01% 527
2026
Q1 		$591K Buy
7,959
+2,134
+37% +$155K 0.01% 529
2025
Q4 		$446K Sell
5,825
-10
-0.2% -$656 0.01% 596
2025
Q3 		$303K Buy
+5,835
New +$285K ﹤0.01% 705

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Fiduciary Trust's BBIO Position: Q2 2026 in Review

Fiduciary Trust increased its BridgeBio Pharma (BBIO) stake by 7.3% in Q2 2026, buying an estimated $40.5K and bringing the position to 8,537 shares worth $636K. The position accounts for 0.01% of the portfolio, ranked #527.

Fiduciary Trust first reported a position in BBIO in Q3 2025 and has held it in 4 quarters since. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Fiduciary Trust held 8,537 shares of BridgeBio Pharma worth $636K as of Q2 2026.
  • Fiduciary Trust bought 578 BridgeBio Pharma shares in Q2 2026, an estimated $40.5K.
  • BridgeBio Pharma made up 0.01% of Fiduciary Trust's portfolio in Q2 2026, its #527 holding.
  • Fiduciary Trust first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 4 quarters since.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.